161 related articles for article (PubMed ID: 28600850)
1. Eight-year follow-up in pediatric living donor kidney recipients receiving alemtuzumab induction.
Kaabak MM; Babenko NN; Shapiro R; Maschan AA; Zokoev AK; Schekaturov SV; Vyunkova JN; Dymova OV
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28600850
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab induction in pediatric kidney transplantation.
Kaabak MM; Babenko NN; Samsonov DV; Sandrikov VA; Maschan AA; Zokoev AK
Pediatr Transplant; 2013 Mar; 17(2):168-78. PubMed ID: 23442101
[TBL] [Abstract][Full Text] [Related]
3. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
[TBL] [Abstract][Full Text] [Related]
4. Primary pediatric live-donor-kidney transplant-recipients' outcomes by immunosuppression induction received in the United States.
Riad S; Jackson S; Chinnakotla S; Verghese P
Pediatr Transplant; 2021 Aug; 25(5):e13925. PubMed ID: 33333629
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience.
Supe-Markovina K; Melquist JJ; Connolly D; DiCarlo HN; Waltzer WC; Fine RN; Darras FS
Pediatr Transplant; 2014 Jun; 18(4):363-8. PubMed ID: 24712738
[TBL] [Abstract][Full Text] [Related]
6. Early outcomes comparing induction with antithymocyte globulin vs alemtuzumab in two steroid-avoidance protocols in pediatric renal transplantation.
Puliyanda DP; Pizzo H; Rodig N; Somers MJG
Pediatr Transplant; 2020 May; 24(3):e13685. PubMed ID: 32112514
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction in deceased donor kidney transplantation.
Huang E; Cho YW; Hayashi R; Bunnapradist S
Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
[TBL] [Abstract][Full Text] [Related]
8. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
[TBL] [Abstract][Full Text] [Related]
10. Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States.
Riad S; Jackson S; Chinnakotla S; Verghese P
Pediatr Transplant; 2021 Aug; 25(5):e13928. PubMed ID: 33314638
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.
Kaufman DB; Leventhal JR; Axelrod D; Gallon LG; Parker MA; Stuart FP
Am J Transplant; 2005 Oct; 5(10):2539-48. PubMed ID: 16162205
[TBL] [Abstract][Full Text] [Related]
12. Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients.
Guthoff M; Berger K; Althaus K; Mühlbacher T; Bakchoul T; Steurer W; Nadalin S; Königsrainer A; Heyne N
BMC Nephrol; 2020 May; 21(1):178. PubMed ID: 32404066
[TBL] [Abstract][Full Text] [Related]
13. Campath induction for kidney transplantation: report of 297 cases.
Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
[TBL] [Abstract][Full Text] [Related]
14. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
15. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
[TBL] [Abstract][Full Text] [Related]
16. Annual trends and triple therapy--1991-2000.
Nishikawa K; Terasaki PI
Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
[TBL] [Abstract][Full Text] [Related]
18. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
Sampaio MS; Chopra B; Sureshkumar KK
Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
[TBL] [Abstract][Full Text] [Related]
20. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.
Tan HP; Donaldson J; Basu A; Unruh M; Randhawa P; Sharma V; Morgan C; McCauley J; Wu C; Shah N; Zeevi A; Shapiro R
Am J Transplant; 2009 Feb; 9(2):355-66. PubMed ID: 19120078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
